CINGAL
Total Payments
$174,705
Transactions
38
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $174,705 | 38 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $174,705 | 38 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee | Anika Therapeutics, Inc. | $174,705 | 0 |
Top Doctors Receiving Payments for CINGAL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tempe, AZ | $174,705 | 38 |
Ad
Manufacturing Companies
- Anika Therapeutics, Inc. $174,705
Product Information
- Type Drug
- Total Payments $174,705
- Total Doctors 0
- Transactions 38
About CINGAL
CINGAL is a drug associated with $174,705 in payments to 0 healthcare providers, recorded across 38 transactions in the CMS Open Payments database. The primary manufacturer is Anika Therapeutics, Inc..
Payment data is available from 2020 to 2020. In 2020, $174,705 was paid across 38 transactions to 0 doctors.
The most common payment nature for CINGAL is "Unspecified" ($174,705, 100.0% of total).
CINGAL is associated with 1 research study, including "A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee" ($174,705).